- Report
- January 2022
- 60 Pages
Global
From €3616EUR$3,950USD£3,073GBP
- Report
- September 2023
- 200 Pages
Global
From €3295EUR$3,599USD£2,800GBP
- Report
- May 2023
- 160 Pages
Global
From €4530EUR$4,949USD£3,850GBP
- Report
- April 2023
- 147 Pages
Global
From €4530EUR$4,949USD£3,850GBP
- Report
- October 2023
- 84 Pages
Canada
From €3204EUR$3,500USD£2,723GBP
- Report
- October 2023
- 89 Pages
Egypt
From €3204EUR$3,500USD£2,723GBP
- Report
- August 2023
- 75 Pages
Israel
From €3204EUR$3,500USD£2,723GBP
- Report
- January 2022
- 115 Pages
Global
From €4348EUR$4,750USD£3,695GBP
- Report
- November 2024
- 108 Pages
Global
From €3500EUR$4,096USD£3,079GBP
- Report
- April 2024
- 280 Pages
Global
From €2288EUR$2,499USD£1,944GBP
€3268EUR$3,570USD£2,777GBP
- Book
- October 2019
China
The anti-hypertensive market within the context of cardiovascular drugs is a large and growing sector of the pharmaceutical industry. It includes a wide range of drugs used to treat high blood pressure, including diuretics, beta blockers, ACE inhibitors, calcium channel blockers, and angiotensin receptor blockers. These drugs are used to reduce the risk of stroke, heart attack, and other cardiovascular diseases. They are also used to reduce the risk of kidney disease, which is often associated with high blood pressure.
The anti-hypertensive market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and GlaxoSmithKline. Other companies, such as AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo, also have a presence in the market. Show Less Read more
